Therapeutic Advances in Chronic Disease (Aug 2023)

Recalcitrant nodular scabies showing excellent response to tofacitinib: five case reports

  • Yu-Kun Zhao,
  • Jing-Fa Lu,
  • Juan-Hua Liu,
  • Hui-Hui Wu,
  • Lu-Li Song,
  • Chun-Lei Wan,
  • Di-Qing Luo

DOI
https://doi.org/10.1177/20406223231195632
Journal volume & issue
Vol. 14

Abstract

Read online

Scabies is a contagious skin condition caused by Sarcoptes scabiei , and it is always associated with an intense, unbearable, nocturnal deteriorating itch. Its presentations include classic burrows, erythema, pruritic papules, pustules, vesicles, and inflammatory nodules, with diffuse or localized distribution on the finger webs, wrist flexors, elbows, axillae, buttocks, genitalia, and breasts. Nodular scabies is an uncommon clinical variant of scabies. Its management is still challenging for some patients up to date, although topical, intralesional or systemic corticosteroids, topical calcineurin inhibitors, and crotamiton as well as cryotherapy alone or in different combinations are used. We here report five male patients of nodular scabies, aged between 14 and 25 years, who had classical scabies that had been cured by sulfur ointment for at least 4 weeks except for their itching nodules, and their residual pruritic nodules also failed in previous treatments including antihistamines, topical applying and intralesional injection of steroids as well as topical tacrolimus in different combinations before being recruited to this study. The patients were administered tofacitinib 5 mg, twice a day, which led to excellent and rapid improvement for both lesions and symptoms after 1–4 weeks of treatment, respectively, without any associations. During 6 months of follow-up, only one had re-infection of scabies associated with nodules that were cured by sulfur ointment and tofacitinib again. No adverse reaction was observed. The present results suggested that tofacitinib might be a potential agent for nodular scabies with excellent response.